Connection

Contact Us
If you have any questions or feedback please contact us.

Search Results to Jennifer R Diamond

This is a "connection" page, showing the details of why an item matched the keywords from your search.

Search Results

Diamond, Jennifer

One or more keywords matched the following items that are connected to Diamond, Jennifer

Item Type	Name
Academic Article	Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.
Academic Article	From bench to bedside: lessons learned in translating preclinical studies in cancer drug development.
Academic Article	Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.
Academic Article	p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer.
Academic Article	An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer.
Academic Article	Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
Grant	The Development of Novel Individualized Therapy for Triple-Negative Breast Cancer
Academic Article	Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer.
Academic Article	A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer.
Academic Article	First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits ?-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer.
Academic Article	Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors.
Academic Article	Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.

Search Criteria

Triacetoneamine N Oxyl